Intellia Therapeutics (NASDAQ:NTLA) Given New $180.00 Price Target at The Goldman Sachs Group

Intellia Therapeutics (NASDAQ:NTLAGet Rating) had its price target dropped by research analysts at The Goldman Sachs Group from $206.00 to $180.00 in a research note issued to investors on Tuesday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target indicates a potential upside of 314.27% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Brookline Capital Acquisition upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 price objective for the company in a research note on Monday, March 7th. Robert W. Baird lowered their price target on shares of Intellia Therapeutics from $146.00 to $83.00 in a research note on Tuesday, March 1st. JMP Securities cut their price objective on shares of Intellia Therapeutics from $165.00 to $110.00 in a report on Monday, May 9th. William Blair initiated coverage on shares of Intellia Therapeutics in a report on Friday, February 18th. They set an “outperform” rating and a $144.00 price target on the stock. Finally, Brookline Capital Management upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 price objective on the stock in a research report on Monday, March 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $139.90.

NASDAQ:NTLA traded down $3.87 during trading hours on Tuesday, reaching $43.45. 5,361 shares of the company were exchanged, compared to its average volume of 1,145,946. The company has a market capitalization of $3.30 billion, a P/E ratio of -8.69 and a beta of 2.14. Intellia Therapeutics has a 1-year low of $38.85 and a 1-year high of $202.73. The business has a 50 day moving average of $58.69 and a 200 day moving average of $86.97.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($1.96) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.85). The firm had revenue of $11.30 million during the quarter, compared to the consensus estimate of $8.57 million. Intellia Therapeutics had a negative net margin of 973.48% and a negative return on equity of 41.00%. The firm’s revenue was up 73.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.69) earnings per share. On average, equities research analysts forecast that Intellia Therapeutics will post -5.77 EPS for the current year.

Several institutional investors have recently made changes to their positions in NTLA. Truist Financial Corp grew its stake in Intellia Therapeutics by 36.2% in the third quarter. Truist Financial Corp now owns 2,914 shares of the company’s stock valued at $391,000 after acquiring an additional 775 shares during the period. Creative Planning acquired a new stake in Intellia Therapeutics during the third quarter worth approximately $243,000. US Bancorp DE boosted its holdings in shares of Intellia Therapeutics by 12.7% in the 3rd quarter. US Bancorp DE now owns 12,845 shares of the company’s stock valued at $1,723,000 after purchasing an additional 1,444 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Intellia Therapeutics by 16.4% in the 3rd quarter. American Century Companies Inc. now owns 71,699 shares of the company’s stock valued at $9,619,000 after acquiring an additional 10,107 shares during the last quarter. Finally, CI Investments Inc. bought a new position in Intellia Therapeutics during the 3rd quarter worth $39,000. 85.89% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics (Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Further Reading

Stock Target Advisor logo

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.